Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain
/in International Publications, Newcastle Disease VirusGenetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy
/in International Publications, Newcastle Disease VirusLocalized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease VirusNatural killer cells: the secret weapon in dendritic cell vaccination strategies
/in Dendritic Cells, International PublicationsNovel approaches and mechanisms of immunotherapy for glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsPhase I dendritic cell p53 peptide vaccine for head and neck cancer
/in Dendritic Cells, International PublicationsDasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma
/in Dendritic Cells, International Publications, Malignant MelanomaDNA fragmentation and caspase-independent programmed cell death by modulated electrohyperthermia
/in Hyperthermia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer